Dr Reddy’s Enters OTC Eyecare Space
US Launch Of Pataday Generic Follows Voltaren And Nicorette Rivals
Executive Summary
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.
You may also be interested in...
Dr Reddy's Adds To OTC Portfolio With Glenmark Deal
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Dr Reddy’s And Perrigo Capitalize On Voltaren Switch
Seven months after GlaxoSmithKline’s Voltaren Arthritis Pain (diclofenac sodium) 1% topical gel was switched to non-prescription status in the US, two companies have begun shipping equivalent OTC versions to retailers.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.